Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.51 |
| ▸ | CYCS | P99999 | 3/20 | 0.51 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.50 |
| ▸ | TOP1 | P11387 | 2/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.43 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297908 | 1.00 | TERT (0.51) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL8865323 | 1.00 | TERT (0.51) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL29556430 | 0.98 | TOP1 (0.50) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL31296593 | 0.98 | TOP1 (0.50) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL249199 | 0.98 | TOP1 (0.50) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL1640992 | 0.94 | TOP1 (0.54) | TERTCYCSENPP2TOP1STAT3 | |
| Temoporfin SCHEMBL6422 | 0.89 | TOP1 (0.43) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL5100886 | 0.89 | TOP1 (0.43) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL17651778 | 0.89 | TOP1 (0.43) | TERTCYCSENPP2TOP1STAT3 | |
| SCHEMBL17651811 | 0.89 | TOP1 (0.43) | TERTCYCSENPP2TOP1STAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11324826-B2 | Multifunctional treatment and diagnostic compositions and methods | ZAMADAR MATIBUR RAHAMAN (US) | 2022-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11324826-B2 | Multifunctional treatment and diagnostic compositions and methods | MDH2, DLD, IDH2 | TERT 493/4885CYCS 171/4885ENPP2 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.